Zhejiang Innoforce Pharmaceuticals names Dr. Dewan Zeng as its new Chief Executive Officer, effective immediately. The company specializes in one-stop-shop services for Advanced Therapy Medicinal Products (ATMP). Dr. Yuling Li retains her role as President, focusing on technology innovation and CDMO operations.
Innoforce expands its manufacturing capacity with a new **GMP-certified facility and corporate headquarters in Hangzhou, China**, supporting **RNA, cell, and gene therapy** production. The site joins existing operations in the **U.S.** to deliver **end-to-end contract development and manufacturing (CDMO) services** for advanced therapies. The move strengthens Innoforce’s ability to serve global supply chains in the growing biopharmaceutical sector.
Innoforce secures an additional **375 million CNY ($58.7M)** in its Series A financing, bringing total raised to **1 billion CNY ($156.6M)**. The biopharmaceutical company, based in Hangzhou, China, follows up on its first tranche of **625 million CNY ($96M)** closed in March 2021. The funding supports its manufacturing and development operations in the biopharmaceutical sector.
Innoforce Pharmaceuticals has opened an Advanced Cell and Gene Therapy Development Facility in Hangzhou, China. The facility supports analytical and process development for cell and gene therapy products, aiding clients in advancing their projects toward clinical trials. This expansion strengthens Innoforce’s capabilities in biopharmaceutical innovation and partnership services.
Innoforce and dMed have partnered to accelerate the development of innovative therapeutics. The collaboration focuses on combining expertise to advance drug discovery and clinical development processes. Both companies aim to streamline the pathway for bringing new treatments to market.
Innoforce and dMed form a partnership to identify and develop clinical-stage therapeutics. The collaboration combines Innoforce’s biopharmaceutical innovation platform and PDMO services with dMed’s clinical CRO expertise in China and the US. Both companies aim to streamline the assessment and advancement of new drug candidates in key global markets.